METHOD FOR PREDICTION OF HER2/NEU EPIDERMAL GROWTH FACTOR RECEPTOR STATUS IN MAIN TUMOR NODE IN BREAST CANCER PATIENTS Russian patent published in 2022 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to oncology, and can be used to predict the status of the Her2/neu epidermal growth factor receptor in the main tumor node in patients with breast cancer. The radiopharmaceutical drug (RPD) "^99mTc-DARPinG3" is administered at a dose of 3000 μg, and after 4 hours, single-photon emission computed tomography of the chest organs is performed, in which the accumulation of the radiopharmaceutical in the breast tumor and the symmetrical area of ​​the opposite mammary gland, selected as a background, is assessed. The tumor/background ratio is calculated 4 hours after the administration of the radiopharmaceutical and the value of the regression equation Y is calculated using the given formula. Next, the probability P of assessing the status of the Her2/neu epidermal growth factor receptor in the primary tumor is determined, and at P≥50%, a high probability is predicted, and at P<50%, a low probability of Her2-positive status of the tumor node tissue.

EFFECT: method provides an increase in the information content of the diagnostic stage, which allows optimizing the prescribed systemic therapy in patients with breast cancer, by evaluating the totality of the most significant indicators.

1 cl, 2 ex